EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OAB
Experts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.
Please see full Prescribing Information for onabotulinumtoxinA, including Boxed Warning.
Sponsored by AbbVie US Medical Affairs
EP: 1.In-Clinic Educational Resource on the OAB Treatment Pathway
EP: 2.EP. 1: An Introduction of the Speakers
EP: 3.EP. 2: The Diagnostic Process of OAB and Initial Patient-Clinician Conversations
EP: 4.EP. 3: The Typical Patient with OAB and Common Signs and Symptoms
EP: 5.EP. 4: The Role of Urodynamic Testing in OAB Evaluation
EP: 6.EP. 5: OAB Treatment: Available Strategies and Rationale for Use
EP: 7.EP. 6: Factors Informing Selection of Pharmacologic Treatment for OAB
EP: 8.Ep. 7: Defining Pharmacologic Treatment Failure in Patients with OAB and Subsequent Treatment Strategies
EP: 9.EP. 8: Patient-Clinician Conversations Regarding Initial Pharmacologic Treatment for OAB
EP: 10.EP. 9: Treatment Goals and Educational Resources for Patients on Initial Pharmacologic Therapy for OAB
EP: 11.EP. 10: Third-Line OAB Therapies and Patient-Centered Decision-Making
EP: 12.EP. 11: Setting Treatment Expectations for Patients with OAB Receiving Third-Line Therapies
EP: 13.EP. 12: OAB Patient Monitoring and Followup Considerations in the Third-Line Treatment Setting
EP: 14.EP. 13: Re-Treatment and Scheduling with OnabotulinumtoxinA
EP: 15.EP. 14: SNM and PTNS for OAB: Device Management and Followup
EP: 16.EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OAB
This content is intended for US/PR Healthcare Professionals.
The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Dr. Goudelocke outlines stand-up urgency in patients with OAB
April 18th 2024"There are plenty of articles written about stress-induced urgency. I, at the time, only found 1 article written in the gynecologic literature about what they called stand-up urgency," according to Colin Goudelocke, MD.
